Partnership EpiLogic Gmbh and Tentamus India

EpiLogic GmbH and Tentamus India have joined forces to offer the services of EpiLogic in India. EpiLogic is currently the market leader in Europe with regards to fungicide resistance monitoring studies and is actively looking to expand its services internationally.

India with a large agricultural sector and a fast-growing population, is highly depended on its food production. Fungal plant pathogens have a significant impact on the Indian food supply and food safety. Fungal plant pathogens can adapt and show resistance to modern fungicidal compounds. To secure and understand the effectiveness of current fungicides, reliable local resistance and adaptation monitoring is required. EpiLogic GmbH has more than 25 years of experience in this field in Europe. Together with Tentamus India they will be actively sharing this experience and expertise on the Indian market.

On February 1st,2024, a first employee was hired to set-up the laboratory in Hyderabad, India. He will work with the team of EpiLogic GmbH to transfer knowledge and expertise. For the Indian market we will be offering existing EpiLogic services, as well as develop new services and fungal plant pathogen studies for the Indian market. One of these new services will be seed health testing. The current plan sees a commercial launch by the end of 2024.

"I believe that the partnership between EpiLogic GmbH and Tentamus India is a great opportunity for EpiLogic to span its wings internationally and allows our existing international customer base to expand their resistance monitoring program to the important Indian market" – says Gijs Manneveld, CEO of EpiLogic GmbH.

“India is a fast-growing agricultural market. A large challenge for India is, pathogen samples are not allowed to be shipped outside of India, requiring a local solution for resistance monitoring. This partnership will benefit both existing global and domestic customers and will eventually fill a gap in the local market.” – says M. Jayapal Reddy, CEO of Tentamus India Private Limited.

“This development at Tentamus India is part of our services expansion strategy and one among the many collaborations done with various Group labs in the recent past. This partnership with EpiLogic will make Tentamus India a key player in resistance monitoring segment in the Indian market” – says Keerthi Vardhan Reddy Vemula, Country Manager India of Tentamus Group.

About EpiLogic GmbH

EpiLogic was founded in 1996 and is a leading player in the Agrochemical Industry. They are specialized in applied phytopathology and related studies on the adaptation and resistance of fungal pathogens on agricultural and horticultural crops to fungicidal agents. EpiLogic offers in vitro and in vivo resistance studies for a large set of fungal pathogens, including molecular R&D capabilities.

About Tentamus India

Tentamus India (formerly Megsan Labs) is a US-FDA Inspected, ISO 17025 accredited, FSSAI approved and DCGI (Drug Controller General of India -Indian FDA) approved laboratory, which provides analytical testing services to food, pharmaceutical and related companies. The services comprise elemental impurity studies, E&L studies, method development & validation and microbiological testing.

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com

Ansprechpartner:
Gijs Manneveld
CEO of EpiLogic GmbH
E-Mail: gijs.manneveld@epilogic.de
Keerthi Vardhan Reddy Vemula
Tentamus India
E-Mail: keerthi.vemula@tentamus.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel